# Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

> **NCT03576443** · PHASE2 · COMPLETED · sponsor: **Nordic Lymphoma Group** · enrollment: 36 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT03576443
- **Lead sponsor:** Nordic Lymphoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-07
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576443, "Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03576443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*